1. Lilly, Boehringer—following AZ—nab Jardiance win in heart failure patients with or without diabetes.
Locked in a heated contest with rival AstraZeneca for the lucrative heart failure market, Eli Lilly and Boehringer Ingelheim are hoping to keep pace with their diabetes med, Jardiance. AstraZeneca struck a major blow in May with an FDA approval for its Farxiga in a novel indication—but Jardiance isn't far behind. more details...


2. FDA approves non-opioid capsaicin pain patch for diabetic neuropathy
The patch (Qutenza, Grünenthal and Averitas Pharma) is a topical, non-systemic, non-opioid pain treatment and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin, according to the release. more details...


3. AstraZeneca's Farxiga backs up kidney disease trial stop with new top-line data
AstraZeneca has shaken up the lucrative heart failure market with diabetes med Farxiga after a major approval earlier this year. But in kidney disease, another blockbuster market, Farxiga also sports promising data, and it could spell a big FDA nod to come. more details...


4. FDA clears smart insulin pen for children with diabetes
As Healio previously reported, the InPen system (Companion Medical) has been commercially available for iOS users since December 2017 and is the only FDA-cleared smart insulin pen paired with an integrated diabetes management app. more details...


5. A Complete List of Diabetes Medications
There are two different types of diabetes: type 1 diabetes and type 2 diabetes. People with either type of diabetes need medications to help keep their blood sugar levels normal. more details...


6. Top 8 Breakthrough Diabetes Treatments You May Have Missed
Even more concerning is the number of Americans who are at risk for these conditions: it was reported by the Centers for Disease Control and Prevention (CDC) in 2017 that close to 100 million people in the U.S. have diabetes or prediabetesmore details...